Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial

키워드

참고문헌 (43)

1. The world health report 2001. Mental health: new understanding, new hope, "World Health Organization", World Health Organization, ~ (2001)
2. Maes M, "The inflammatory & neurodegenerative (I&ND)hypothesis of depression: leads for future research and new drug developments in depression", Metab Brain Dis, 24, pp.27~53 (2009)
3. Schiepers OJ, "Cytokines and major depression", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.201~217 (2005)
4. Nishida A, "Antidepressant drugs and cytokines in mood disorders", Int Immunopharmacol, 2, pp.1619~1626 (2002)
5. Peet M, "Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients", Biol Psychiatry, 43, pp.315~319 (1998)
6. Maes M, "Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness", J Affect Disord, 58, pp.241~246 (2000)
7. Maes M, "Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients", Psychiatry Res, 85, pp.275~291 (1999)
8. Bilici M, "Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments", J Affect Disord, 64, pp.43~51 (2001)
9. Selley ML., "Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression", J Affect Disord, 80, pp.249~256 (2004)
10. Khanzode SD, "Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors", Redox Rep, 8, pp.365~370 (2003)
11. Forlenza MJ, "Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression", Psychosom Med, 68, pp.1~7 (2006)
12. Gałecki P, "The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder", J Affect Disord, 138, pp.360~366 (2012)
13. Maes M, "Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression", J Affect Disord, 149, pp.23~29 (2013)
14. Allen SJ, "Clinical relevance of the neurotrophins and their receptors", Clin Sci (Lond), 110, pp.175~191 (2006)
15. Castrén E, "The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity", Dev Neurobiol, 70, pp.289~297 (2010)
16. Otsuki K, "Altered expression of neurotrophic factors in patients with major depression", J Psychiatr Res, 42, pp.1145~1153 (2008)
17. Berk M, "Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors", Neurosci Biobehav Rev, 35, pp.804~817 (2011)
18. Dean OM, "Minocycline:therapeutic potential in psychiatry", CNS Drugs, 26, pp.391~401 (2012)
19. 김성수, "Inhibitory Action of Minocycline on Lipopolysaccharide-Induced Release of Nitric Oxide and Prostaglandin E2 in BV2 Microglial Cells", Archives of Pharmacal Research, 27(3), pp.314~318 (2004), 대한약학회
20. Ahuja M, "Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity", Toxicology, 244, pp.111~122 (2008)
21. Morimoto N, "Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage", Brain Res, 1044, pp.8~15 (2005)
22. Homsi S, "Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice", Brain Res, 1291, pp.122~132 (2009)
23. Orio L, "A study on the mechanisms by which minocycline protects against MDMA (‘ecstasy’)-induced neurotoxicity of 5-HT cortical neurons", Neurotox Res, 18, pp.187~199 (2010)
24. Kernt M, "Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2", Clin Ophthalmol, 4, pp.591~604 (2010)
25. factor eIF4AI, "PLoS One", 2010, e15430~
26. Homsi S, "Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study", J Neurotrauma, 27, pp.911~921 (2010)
27. Kim BJ, "Reduced neurogenesis after suppressed inflammation by minocycline in transient cerebral ischemia in rat", J Neurol Sci, 279, pp.70~75 (2009)
28. Liu Z, "Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia", Stroke, 38, pp.146~152 (2007)
29. Zhong J, "Hydrogen peroxide attenuates insulinlike growth factor-1 neuroprotective effect, prevented by minocycline", Neurochem Int, 51, pp.398~404 (2007)
30. Garcia-Martinez EM, "Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells", Biochem Pharmacol, 79, pp.239~250 (2010)
31. Kraus RL, "Antioxidant properties of minocycline:neuroprotection in an oxidative stress assay and direct radical-scavenging activity", J Neurochem, 94, pp.819~827 (2005)
32. Zhang L, "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1381~1393 (2006)
33. Zhang L, "Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine", Neuropsychopharmacology, 32, pp.2004~2010 (2007)
34. Molina-Hernández M, "Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1660~1666 (2008)
35. Deak T, "Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide", Behav Brain Res, 160, pp.125~134 (2005)
36. Arakawa S, "Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline", Pharmacol Biochem Behav, 100, pp.601~606 (2012)
37. Pae CU, "Does minocycline have antidepressant effect?", Biomed Pharmacother, 62, pp.308~311 (2008)
38. Miyaoka T, "Possible antipsychotic effects of minocycline in patients with schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.304~307 (2007)
39. Miyaoka T, "Minocycline as adjunctive therapy for schizophrenia: an open-label study", Clin Neuropharmacol, 31, pp.287~292 (2008)
40. Levkovitz Y, "A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia", J Clin Psychiatry, 71, pp.138~149 (2010)
41. Levine J, "Possible antidepressant effect of minocycline", Am J Psychiatry, 153, pp.582~ (1996)
42. Stolley PD, "Sample size calculations for clinical pharmacology studies", Clin Pharmacol Ther, 39, pp.489~490 (1986)
43. Bech P, "Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression", Int J Neuropsychopharmacol, 7, pp.283~290 (2004)

관련 논문AI추천